Phase II study of methyl-CCNU in the treatment of advanced pancreatic carcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D001791:Blood Platelet Disorders / Q000139:chemically induced; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D012673:Semustine / Q000627:therapeutic use* / Q000633:toxicity
D009607:Nitrosourea Compounds; D012673:Semustine